Skip to main content

Table 1 Characteristics of included network meta-analyses, categorized by sponsorship status

From: Does type of funding affect reporting in network meta-analysis? A scoping review of network meta-analyses

 

Industry-sponsored

( N  = 136)

Non-sponsored

( N  = 208)

Publicly-sponsored

( N  = 314)

Overall

( N  = 658)

Continent of corresponding author

 Africa

1 (1%)

3 (1%)

0 (0%)

4 (1%)

 Asia

11 (8%)

92 (45%)

161 (50%)

264 (40%)

 Australia

1 (1%)

3 (1%)

2 (1%)

6 (1%)

 Europe

71 (52%)

56 (27%)

80 (26%)

207 (31%)

 North America

52 (38%)

44 (21%)

63 (20%)

159 (24%)

 Oceania

0 (0%)

3 (1%)

2 (1%)

5 (1%)

 South America

0 (0%)

7 (4%)

6 (2%)

13 (2%)

Disease category

 Allergy and immunology

2 (2%)

0 (0%)

0 (0%)

2 (0%)

 Cardiology

9 (7%)

27 (13%)

20 (5%)

56 (9%)

 Dermatology

6 (4%)

8 (4%)

9 (3%)

23 (3%)

 Endocrinology

19 (14%)

15 (7%)

37 (11%)

71 (11%)

 Gastroenterology

6 (4%)

23 (11%)

27 (8%)

56 (9%)

 Hematology

7 (5%)

6 (3%)

8 (3%)

21 (3%)

 infectious disease

9 (7%)

17 (8%)

24 (8%)

50 (8%)

 Neurology

12 (9%)

14 (7%)

16 (5%)

42 (6%)

 Obstetrics and gynecology

1 (1%)

4 (2%)

6 (2%)

11 (2%)

 Oncology

17 (12%)

32 (15%)

50 (16%)

99 (15%)

 Ophthalmology

1 (1%)

1 (1%)

6 (2%)

8 (1%)

 Psychiatry

7 (5%)

14 (7%)

24 (8%)

45 (7%)

 Respirology

15 (11%)

10 (5%)

15 (5%)

40 (6%)

 Rheumatology

21 (15%)

13 (6%)

40 (13%)

74 (11%)

 Urology

4 (3%)

2 (1%)

7 (2%)

13 (2%)

 Dentistry

0 (0%)

4 (2%)

2 (1%)

6 (1%)

 General Surgery

0 (0%)

3 (1%)

4 (1%)

7 (1%)

 Nephrology

0 (0%)

10 (5%)

14 (5%)

24 (3%)

 Orthopedic surgery

0 (0%)

3 (1%)

3 (1%)

6 (1%)

 Pediatrics

0 (0%)

2 (1%)

2 (1%)

4 (1%)

Outcome typea

 Objective

48 (35%)

41 (20%)

77 (25%)

166 (25%)

 Semi-objective

25 (19%)

48 (23%)

72 (23%)

145 (22%)

 Subjective

63 (46%)

119 (57%)

165 (52%)

347 (53%)

Efficacy or safety outcomea

 Efficacy

131 (96%)

179 (86%)

288 (92%)

598 (91%)

 Safety

5 (4%)

29 (14%)

26 (8%)

60 (9%)

Type of treatment comparison

 Pharmacologic vs pharmacologic

37 (27%)

71 (34%)

93 (30%)

201 (30%)

 Pharmacologic vs placebo

99 (73%)

137 (66%)

221 (70%)

457 (70%)

Number of RCTs in NMAa

 Median [IQR]

20

[12–33]

17

[11–33]

22

[13–44]

20

[12–37]

 Not reported

4 (3%)

3 (1%)

0 (0%)

7 (1%)

Number of participants in NMAa

 Median [IQR]

7765

[4332–17150]

4992

[2987–13806]

6515

[2722–18247]

6283

[3071–16230]

 Not reported

32 (24%)

24 (11%)

16 (5%)

72 (11%)

Number of interventions in NMAa

 Median [IQR]

8

[6–11]

7

[5–9]

7

[5–10]

7

[5–10]

 Not reported

4 (3%)

2 (1%)

0 (0%)

6 (1%)

Number of nodes in NMAa

 Median [IQR]

8

[6–11]

7

[5–10]

8

[6–12]

8

[5–11]

 Not reported

6 (4%)

3 (1%)

0 (0%)

9 (1%)

Number of interventions manufactured by the industry sponsor in NMAa

 Median [IQR]

1

[1, 2]

NA

[NA–NA]

NA

[NA–NA]

1

[1, 2]

 Not reported

0 (0%)

208 (100%)

314 (100%)

522 (79%)

  1. Abbreviations: IQR interquartile range, NA not applicable, NMA network meta-analysis, RCT randomised controlled trial
  2. aCharacteristics as reported in the primary outcome of the systematic review with NMA